David Campbell, Ph.D., is the President and Chief Executive Officer at JANUX THERAPEUTICS INC, a biopharmaceutical company focused on developing novel T cell engager therapies for cancer treatment. With a robust background in drug discovery and development, Dr. Campbell brings extensive experience and leadership to his role. He earned his Ph.D. in Organic Chemistry from the University of California, Berkeley, and has held various leadership positions in the biopharmaceutical industry, including roles at Amgen and Vertex Pharmaceuticals. At JANUX THERAPEUTICS, Dr. Campbell oversees the company's strategic direction and operational execution, guiding the development of its innovative T cell engager platform. Under his leadership, JANUX has made significant strides in advancing its pipeline of therapies, which aim to enhance the body's immune response to target and destroy cancer cells more effectively. His expertise in medicinal chemistry and drug development has been instrumental in driving the company's mission to bring transformative treatments to patients with cancer. Dr. Campbell's career is marked by numerous achievements, including the successful development and advancement of several drug candidates through clinical trials. His work at Amgen, for instance, contributed to the development of novel therapeutics in oncology and other therapeutic areas. At Vertex, he played a key role in the discovery and development of groundbreaking treatments for cystic fibrosis. His leadership at JANUX THERAPEUTICS continues to build on these accomplishments, positioning the company as a leader in the field of immuno-oncology.